BeiGene, Ltd.
BGNE
주식 순위
#1179
BeiGene, Ltd. is a global biotechnology enterprise that operates across the... BeiGene, Ltd. is a global biotechnology enterprise that operates across the entire pharmaceutical value chain, encompassing the research, development, production, and worldwide commercialization of diverse therapeutic agents. The company's commercially available product lineup includes several important medicines: BRUKINSA, an agent used for relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab, prescribed for R/R classical Hodgkin's lymphoma; REVLIMID, indicated for multiple myeloma; VIDAZA, which addresses myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA, a treatment for giant cell tumor of bone; BLINCYTO, for acute lymphoblastic leukemia; KYPROLIS, another therapy for R/R multiple myeloma; SYLVANT, targeting idiopathic multicentric Castleman disease; QARZIBA, for neuroblastoma; Pamiparib, applicable to various solid tumors; and Pobevcy, indicated for metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). Within its robust clinical development pipeline, BeiGene is actively advancing numerous investigational compounds. Key candidates include Zanubrutinib, a BTK inhibitor designed to combat lymphomas; Tislelizumab, an anti-PD-1 antibody under investigation for a spectrum of solid and hematological cancers; Lifirafenib and BGB-3245, both in trials for melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor targeting NSCLC, melanoma, and other solid tumors. Further expanding its clinical assets are BGB-A333, a PD-L1 inhibitor for diverse solid tumors; Ociperlimab, a TIGIT inhibitor also aimed at various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor for mature B-cell malignancies; BGB-A445, an OX40 agonist antibody for solid tumors; Zanidatamab, a bispecific HER2 inhibitor addressing breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor for a range of solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene has also established strategic alliances with prominent industry partners, including Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. The company, incorporated in 2010, maintains its corporate headquarters in Cambridge, Massachusetts.
주가
$184.00
마지막 동기화: 2025-01-02
시가총액
$19.28B
변동 (1일)
-0.38%
변동 (1년)
0.00%
국가
US
거래 BeiGene, Ltd. (BGNE)
카테고리
Healthcare
BeiGene, Ltd. (BGNE)의 매출
Jun 2026 기준 매출 TTM: $6.13B
BeiGene, Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $6.13B입니다. 2023년에 회사는 $2.46B의 수익을 올렸으며 이는 2022년의 $1.42B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
BeiGene, Ltd.의 수익 기록 (2013 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $6.13B | 60.85% |
| 2024 | $3.81B | 54.96% |
| 2023 | $2.46B | 73.65% |
| 2022 | $1.42B | 20.37% |
| 2021 | $1.18B | 280.83% |
| 2020 | $308.87M | -27.87% |
| 2019 | $428.21M | 116.03% |
| 2018 | $198.22M | -16.85% |
| 2017 | $238.39M | 22,179.16% |
| 2016 | $1.07M | -87.86% |
| 2015 | $8.82M | -32.37% |
| 2014 | $13.04M | 16.93% |
| 2013 | $11.15M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 105.98% |
US
|
|
| $2.23B | -63.65% |
US
|
|
| $15.74B | 156.88% |
AU
|
|
| $6.02B | -1.76% |
NL
|
|
| - | - |
CH
|
